Comparing regimens ( Bismuth sub-citrate , Omeprazole , Amoxicillin , Clarithromycin , Tinidazole ) and ( Bismuth sub citrate , Omeprazole , Tetracycline , Metronidazole , Ofloxacin ) on the eradication rate of Helicobacter pylori infection in non responder dyspeptic patients

Comparing the five-drug regimen ( Bismuth sub-citrate , Omeprazole , Amoxicillin , Clarithromycin , Tinidazole ) and ( Bismuth sub citrate , Omeprazole , Tetracycline , Metronidazole , Ofloxacin ) on the eradication rate of Helicobacter pylori infection in non responder dyspeptic patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201103011155N11

Enrollment

Unknown

Registered

2011-07-03

Start date

2011-02-09

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dyspepsia. Dyspepsia

Interventions

Intervention 1: The first group treated with diet five drug protocol I ( Bismuth sub citrate 240 miligeram two time in day Construction Company Kimdaru drug 120 miligeram of two every 12 hours is give

Treatment - Drugs

The first group treated with diet five drug protocol I ( Bismuth sub citrate 240 miligeram two time in day Construction Company Kimdaru drug 120 miligeram of two every 12 hours is given , Omeprazole 2

Another group treated with protocol II (Bismuth sub citrate 240 miligeram two time in day Construction Co Kimydaru one number per 12 hours , Omeprazole 20 miligeram two time in day Construction Compa

Eligibility

Sex/Gender

All

Age

15 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion: In this study , helicobacter pylori positive patients over 15 years and less than 65 years that under drug treatment regiment quadriple or triple placed urea breath test (UBT) using carbon 14 (C14 or C13 or stoolAg) with the European protocol again have been positive , will enter the study. Exclusion : Pregnant women , Patients with gastric malignancy , Cirrhosis , Patients with allergy to Amoxicillin or Clarithromycin , Omeprazole , Tetracycline , Ofloxacin , Metronidazole and Tinidazole , Colestramin Consumption , Renal failure , History of seizures , Blood disorders , Fauvism and treatment of patients with incomplete (less than 80%) will be excluded.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Helicobacter pylori eradication. Timepoint: 12 week. Method of measurement: ureas breath test with c14 and stool antigen.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarahnaz Joukar

Gastrointestinal and Liver Diseases Research Center

info@gldrc.org+98 13 1553 5116

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026